S-1/A: Virpax Pharmaceuticals Seeks Up to $4.7 Million in Public Offering to Advance Drug Development

Virpax Pharmaceuticals is offering up to 2,415,459 shares of common stock and pre-funded warrants in a best efforts public offering to fund drug development and general corporate purposes.

Summary

• Virpax Pharmaceuticals is conducting a best efforts public offering of up to 2,415,459 shares of common stock and pre-funded warrants.
• The offering aims to raise approximately $4.7 million in net proceeds, assuming a public offering price of $2.07 per share and no issuance of pre-funded warrants.
• The company intends to use the net proceeds to fund drug development activities, working capital, and general corporate purposes, including potentially $1.7 million for marketing and advertising services.
• The offering will terminate on April 15, 2025, unless fully subscribed or terminated earlier.
• Spartan Capital Securities, LLC is acting as the exclusive placement agent for the offering.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol VRPX.
• Virpax is a preclinical-stage pharmaceutical company focused on developing novel drug delivery systems for pain management and CNS disorders.
• The company's portfolio includes product candidates such as Probudur, Envelta, NobrXiol, AnQlar, and Epoladerm.
• Virpax anticipates commencing clinical trials for Probudur in 2025 and Envelta in 2026, but there are no assurances that the trials will commence on the anticipated timeline presented, or at all.
• The company has implemented significant cost-cutting measures, including eliminating directors and officers insurance coverage.
• Virpax reported a stockholders deficit of $0.9 million in its Form 10-K for the year ended December 31, 2024.
• The company received a decision letter from the Nasdaq Hearings Panel, granting the company's request to continue its listing on Nasdaq, subject to certain conditions, including demonstrating compliance with the Minimum Stockholders Equity Rule by April 1, 2025.
• The company has been given until April 2, 2025, to regain compliance with the Minimum Bid Price Rule.
• The company has recently entered into investor relations agreements with IR Agency LLC and Sideways Frequency LLC for marketing and advertising services, with fees of $1.7 million and $300,000, respectively.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company is actively seeking funding and has promising drug candidates, it faces significant financial challenges, including a stockholders deficit, cost-cutting measures, and Nasdaq compliance issues. The lack of D&O insurance and potential difficulties in retaining key personnel add to the negative outlook.

Positives

• The company is actively seeking funding to advance its drug development programs.
• Virpax has exclusive global rights to several proprietary patented technologies.
• The company has a diverse portfolio of preclinical-stage product candidates.
• The Nasdaq Hearings Panel granted the company's request to continue its listing on Nasdaq, subject to certain conditions.

Negatives

• The company has a limited operating history and has consumed substantial amounts of cash since inception.
• Virpax reported a stockholders deficit of $0.9 million in its Form 10-K for the year ended December 31, 2024.
• The company has implemented significant cost-cutting measures, including eliminating directors and officers insurance coverage, which may affect retention and expose directors and officers to personal liability.
• The company may not be able to comply with the Minimum Stockholders Equity Rule even after this offering due to its cash burn rate, operating expenses, and payment obligations.
• The company has been given until April 2, 2025, to regain compliance with the Minimum Bid Price Rule.
• Recent litigation has negatively impacted the company's cash position.

Risks

• The company requires substantial additional capital to fund its operations, and failure to obtain necessary financing could hinder drug development and commercialization.
• Recent cost-cutting measures may negatively affect employee morale and retention, potentially disrupting business operations and delaying product development timelines.
• The elimination of directors and officers insurance may affect retention, expose directors and officers to personal liability, and impact the company's financial condition.
• The company may not be able to maintain a listing of its common stock on Nasdaq.
• The company's management has broad discretion in using the net proceeds from the offering.
• The company may face challenges in retaining key personnel and maintaining business continuity as a result of recent cost-cutting measures, including salary reductions, which may also affect product development and timelines.
• The company's arrangements relating to independent contractors may be questioned by the relevant authorities and if such authorities determine that such arrangements constitute employment, the company may be liable to make certain back payments and payments of interest and penalties to such authorities.
• The company will need additional future financing which may not be available on acceptable terms, if at all and will result in the issuance of additional securities being issued which will cause investors to experience further dilution.

Future Outlook

The company anticipates commencing clinical trials for Probudur in 2025 and Envelta in 2026, but there are no assurances that the trials will commence on the anticipated timeline presented, or at all. The company will require additional funding if there is a delay in commencing a clinical trial.

Industry Context

Virpax operates in the pharmaceutical industry, specifically focusing on developing novel drug delivery systems for pain management and CNS disorders. The company's strategy involves advancing non-opioid and non-addictive pain management treatments. The industry is characterized by intense competition, high regulatory hurdles, and significant capital requirements.

Comparison to Industry Standards

• Virpax is a preclinical-stage company, making direct comparisons to established pharmaceutical companies difficult.
• Comparable companies in the drug delivery space include Alkermes, which focuses on developing innovative medicines using proprietary drug delivery technologies, and Durect Corporation, which develops sustained-release drug delivery systems.
• Virpax's reliance on preclinical assets and the need for further clinical development pose challenges in benchmarking against companies with approved products and established revenue streams.
• The company's cost-cutting measures, including the elimination of D&O insurance, are unusual and may raise concerns about risk management and corporate governance compared to industry standards.

Management Changes

Corporate Governance

Legal Proceedings

• The company entered into a Settlement Agreement and Mutual Release with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals Inc. to resolve all claims related to litigation in the Chancery Court of the State of Delaware.
• The company agreed to pay Sorrento and Scilex a total cash payment of $6 million and royalties of 6% of annual net sales of products developed from drug candidates Epoladerm, Probudur and Envelta.
• The Plaintiffs can still pursue claims against Mr. Mack.
• The company received a letter from legal counsel to Gerald Bruce and Vinay Shah regarding their employment agreements, alleging violations of their employment agreements.

Related Party Transactions

• The company entered into an Independent Contractor Agreement with Jatinder Dhaliwal, the Company's Chief Executive Officer, through his personal corporation, Jat Consulting Corp.
• The company entered into an Independent Contractor Agreement with Usama Chaudhry as Chief Financial Officer of the Company under an Independent Contractor Agreement with Chaudhry U Consulting Inc.

Stakeholder Impact

• Shareholders may experience dilution as a result of the public offering.
• Employees may be affected by the cost-cutting measures and potential disruptions to business operations.
• The company's ability to develop and commercialize its product candidates will impact patients and the healthcare industry.
• The company's financial stability and ability to meet its obligations will impact its suppliers and creditors.

Next Steps

• The company needs to raise additional funds to continue its operations and meet Nasdaq compliance requirements.
• The company needs to commence clinical trials for Probudur and Envelta.
• The company needs to regain compliance with the Minimum Bid Price Rule by April 2, 2025.
• The company needs to file public disclosures describing the transactions and financial measures undertaken to regain compliance with Minimum Stockholders Equity Rule by April 1, 2025.

Key Dates

Keywords

public offering, common stock, pre-funded warrants, Virpax Pharmaceuticals, drug development, clinical trials, Nasdaq, financing, pharmaceuticals, biotechnology